Acacia to Seek $232 Million in London IPO for Drug DevelopmentBy
Medicines aim to treat nausea after surgery, chemotherapy
Stock expected to trade next month on London stock exchange
Acacia Pharma plans to raise about 150 million pounds ($232 million) by selling new shares in an initial public offering to fund the development of four medicines designed to quell post-surgery and post-chemotherapy symptoms such as vomiting for cancer patients.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.